Reata is committed to developing novel therapeutics for patients with serious and life-threatening diseases. AS and FA are diverse, chronic diseases in which mitochondrial dysfunction, inflammation, and oxidative stress are implicated. Mitochondrial dysfunction occurs when cellular energy production is impaired in favor of production of proinflammatory mediators including cytokines and ROS. Chronic inflammation can lead to tissue fibrosis, organ remodeling, or other organ damage.1